| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalomyelitis, Autoimmune, Experimental | 34 | 2024 | 54 | 8.100 |
Why?
|
| Multiple Sclerosis | 22 | 2024 | 45 | 6.200 |
Why?
|
| Autoimmune Diseases | 8 | 2020 | 57 | 2.510 |
Why?
|
| Peptide Fragments | 19 | 2021 | 308 | 2.350 |
Why?
|
| Pertussis Toxin | 9 | 2013 | 27 | 2.030 |
Why?
|
| Th1 Cells | 15 | 2018 | 92 | 2.010 |
Why?
|
| T-Lymphocytes | 17 | 2018 | 357 | 1.950 |
Why?
|
| Lymphocyte Activation | 15 | 2021 | 236 | 1.930 |
Why?
|
| Myelin Proteolipid Protein | 8 | 2021 | 12 | 1.720 |
Why?
|
| Adjuvants, Immunologic | 6 | 2021 | 107 | 1.670 |
Why?
|
| Cytokines | 15 | 2016 | 602 | 1.640 |
Why?
|
| T-Lymphocyte Subsets | 10 | 2014 | 88 | 1.640 |
Why?
|
| Central Nervous System | 9 | 2021 | 135 | 1.490 |
Why?
|
| Mice | 65 | 2024 | 5913 | 1.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2020 | 259 | 1.430 |
Why?
|
| Animals | 80 | 2024 | 15081 | 1.400 |
Why?
|
| Interferon-gamma | 16 | 2016 | 250 | 1.290 |
Why?
|
| Th2 Cells | 11 | 2014 | 58 | 1.260 |
Why?
|
| HLA-DR4 Antigen | 7 | 2018 | 20 | 1.200 |
Why?
|
| Mice, Inbred C57BL | 29 | 2024 | 1609 | 1.200 |
Why?
|
| HLA-DR2 Antigen | 3 | 2018 | 4 | 1.180 |
Why?
|
| Freund's Adjuvant | 10 | 2021 | 14 | 1.140 |
Why?
|
| Epitopes, T-Lymphocyte | 13 | 2013 | 57 | 1.140 |
Why?
|
| Antigen Presentation | 8 | 2021 | 54 | 1.110 |
Why?
|
| Mice, Transgenic | 20 | 2020 | 617 | 1.060 |
Why?
|
| Inflammation | 5 | 2019 | 618 | 1.000 |
Why?
|
| Immunologic Memory | 7 | 2020 | 38 | 0.990 |
Why?
|
| Autoimmunity | 10 | 2024 | 53 | 0.990 |
Why?
|
| Myelin-Associated Glycoprotein | 6 | 2011 | 17 | 0.940 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2019 | 2 | 0.880 |
Why?
|
| Quorum Sensing | 1 | 2022 | 13 | 0.860 |
Why?
|
| Lipids | 5 | 2014 | 235 | 0.840 |
Why?
|
| Cell Wall | 2 | 2021 | 53 | 0.810 |
Why?
|
| Astrocytes | 2 | 2019 | 255 | 0.810 |
Why?
|
| Capsules | 1 | 2021 | 25 | 0.790 |
Why?
|
| Proteoglycans | 1 | 2021 | 47 | 0.770 |
Why?
|
| Myeloid Cells | 3 | 2021 | 29 | 0.760 |
Why?
|
| Antigen-Presenting Cells | 7 | 2015 | 30 | 0.720 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 12 | 0.710 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2021 | 206 | 0.690 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 4 | 2016 | 8 | 0.680 |
Why?
|
| Bacteria | 1 | 2022 | 255 | 0.680 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 290 | 0.670 |
Why?
|
| Antigens | 3 | 2018 | 56 | 0.670 |
Why?
|
| Humans | 46 | 2024 | 37093 | 0.670 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 15 | 0.660 |
Why?
|
| Neuroglia | 1 | 2019 | 124 | 0.620 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 21 | 0.610 |
Why?
|
| HLA-DR Antigens | 6 | 2011 | 21 | 0.600 |
Why?
|
| Cell Differentiation | 5 | 2020 | 587 | 0.590 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2009 | 99 | 0.590 |
Why?
|
| Disease Models, Animal | 10 | 2024 | 1371 | 0.580 |
Why?
|
| Cell Lineage | 2 | 2020 | 90 | 0.570 |
Why?
|
| Francisella tularensis | 6 | 2016 | 115 | 0.550 |
Why?
|
| Spinal Cord | 3 | 2013 | 94 | 0.540 |
Why?
|
| Proteomics | 6 | 2021 | 325 | 0.530 |
Why?
|
| Myelin Sheath | 1 | 2015 | 48 | 0.520 |
Why?
|
| Mice, Knockout | 13 | 2018 | 933 | 0.510 |
Why?
|
| Bacterial Vaccines | 7 | 2016 | 125 | 0.510 |
Why?
|
| Cells, Cultured | 12 | 2021 | 1518 | 0.510 |
Why?
|
| Interleukin-17 | 5 | 2016 | 53 | 0.510 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 11 | 0.500 |
Why?
|
| Lipid Peroxidation | 1 | 2015 | 140 | 0.500 |
Why?
|
| Body Fluids | 1 | 2014 | 17 | 0.500 |
Why?
|
| Female | 39 | 2024 | 20969 | 0.470 |
Why?
|
| Mast Cells | 5 | 2013 | 81 | 0.470 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 119 | 0.470 |
Why?
|
| Chlamydia Infections | 6 | 2013 | 196 | 0.460 |
Why?
|
| Immunotherapy | 2 | 2017 | 95 | 0.450 |
Why?
|
| Transcription Factors | 1 | 2018 | 681 | 0.440 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2011 | 159 | 0.440 |
Why?
|
| Chlamydia muridarum | 6 | 2013 | 104 | 0.430 |
Why?
|
| Mice, Inbred Strains | 8 | 2013 | 116 | 0.410 |
Why?
|
| Proteins | 1 | 2014 | 369 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2009 | 103 | 0.400 |
Why?
|
| Virulence Factors, Bordetella | 2 | 2002 | 7 | 0.400 |
Why?
|
| Thymus Gland | 2 | 2009 | 81 | 0.400 |
Why?
|
| Neurons | 1 | 2019 | 1175 | 0.400 |
Why?
|
| T-Box Domain Proteins | 1 | 2011 | 7 | 0.390 |
Why?
|
| Integrin alpha4beta1 | 1 | 2011 | 5 | 0.390 |
Why?
|
| Anaphylaxis | 1 | 2011 | 14 | 0.380 |
Why?
|
| Mice, Inbred BALB C | 14 | 2016 | 661 | 0.360 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1207 | 0.360 |
Why?
|
| Interleukin-4 | 6 | 2012 | 72 | 0.360 |
Why?
|
| Neuromyelitis Optica | 2 | 2024 | 2 | 0.360 |
Why?
|
| Autoantibodies | 4 | 2024 | 103 | 0.350 |
Why?
|
| Proteome | 4 | 2017 | 144 | 0.340 |
Why?
|
| MicroRNAs | 1 | 2014 | 426 | 0.340 |
Why?
|
| Immunization | 6 | 2013 | 92 | 0.330 |
Why?
|
| Cell Movement | 5 | 2013 | 571 | 0.330 |
Why?
|
| Immune Tolerance | 6 | 2008 | 65 | 0.330 |
Why?
|
| Myelin Proteins | 6 | 2011 | 26 | 0.310 |
Why?
|
| Tularemia | 6 | 2016 | 114 | 0.300 |
Why?
|
| Neoplasms | 1 | 2017 | 1103 | 0.300 |
Why?
|
| Brain | 3 | 2013 | 1346 | 0.290 |
Why?
|
| Apoptosis | 3 | 2015 | 1398 | 0.290 |
Why?
|
| Cell Survival | 1 | 2009 | 864 | 0.280 |
Why?
|
| Adoptive Transfer | 5 | 2013 | 48 | 0.270 |
Why?
|
| Animals, Newborn | 5 | 2010 | 343 | 0.270 |
Why?
|
| Signal Transduction | 5 | 2022 | 1908 | 0.260 |
Why?
|
| Genital Diseases, Female | 3 | 2011 | 37 | 0.260 |
Why?
|
| Interleukin-6 | 3 | 2021 | 153 | 0.250 |
Why?
|
| Injections, Intraperitoneal | 5 | 2013 | 60 | 0.250 |
Why?
|
| Antigens, Bacterial | 3 | 2010 | 132 | 0.240 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 196 | 0.240 |
Why?
|
| Immunodominant Epitopes | 5 | 2012 | 27 | 0.240 |
Why?
|
| Suramin | 1 | 2004 | 4 | 0.240 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 60 | 0.230 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 185 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 356 | 0.220 |
Why?
|
| Receptors, Cytokine | 2 | 2013 | 12 | 0.210 |
Why?
|
| Cross Infection | 1 | 2022 | 38 | 0.210 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 33 | 0.210 |
Why?
|
| Immune System | 1 | 2022 | 41 | 0.210 |
Why?
|
| Autoantigens | 7 | 2005 | 81 | 0.210 |
Why?
|
| Cell Count | 1 | 2022 | 135 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2024 | 208 | 0.200 |
Why?
|
| Mammals | 1 | 2022 | 105 | 0.200 |
Why?
|
| Flow Cytometry | 3 | 2015 | 399 | 0.200 |
Why?
|
| Integrin alpha4 | 1 | 2021 | 2 | 0.200 |
Why?
|
| Incidence | 2 | 2024 | 922 | 0.200 |
Why?
|
| Serum Amyloid A Protein | 1 | 2021 | 14 | 0.200 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 24 | 0.190 |
Why?
|
| Systems Biology | 1 | 2020 | 22 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2021 | 121 | 0.190 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 33 | 0.180 |
Why?
|
| Cell Communication | 2 | 2019 | 97 | 0.180 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 90 | 0.180 |
Why?
|
| Integrins | 1 | 2020 | 51 | 0.180 |
Why?
|
| Organ Specificity | 3 | 2018 | 129 | 0.180 |
Why?
|
| Recombination, Genetic | 1 | 2020 | 93 | 0.180 |
Why?
|
| Zebrafish Proteins | 1 | 2020 | 47 | 0.170 |
Why?
|
| Immunoglobulin G | 6 | 2007 | 237 | 0.170 |
Why?
|
| Disease Progression | 2 | 2019 | 601 | 0.170 |
Why?
|
| Mice, SCID | 4 | 2011 | 150 | 0.170 |
Why?
|
| NADP | 1 | 2019 | 38 | 0.170 |
Why?
|
| Antigens, CD20 | 1 | 2018 | 4 | 0.170 |
Why?
|
| Interleukin-12 | 3 | 2010 | 47 | 0.170 |
Why?
|
| Glucans | 1 | 2018 | 6 | 0.170 |
Why?
|
| Neuralgia | 1 | 2019 | 14 | 0.160 |
Why?
|
| Protozoan Vaccines | 1 | 2018 | 15 | 0.160 |
Why?
|
| Chitin | 1 | 2018 | 19 | 0.160 |
Why?
|
| Genomics | 1 | 2020 | 223 | 0.160 |
Why?
|
| Muramidase | 5 | 2004 | 22 | 0.160 |
Why?
|
| Coccidioides | 1 | 2018 | 51 | 0.160 |
Why?
|
| Coccidioidomycosis | 1 | 2018 | 46 | 0.160 |
Why?
|
| Spleen | 6 | 2016 | 199 | 0.160 |
Why?
|
| Vaccination | 3 | 2017 | 288 | 0.160 |
Why?
|
| Receptors, Interferon | 2 | 2015 | 14 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2018 | 45 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 43 | 0.150 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 24 | 0.150 |
Why?
|
| Receptors, Peptide | 1 | 2017 | 23 | 0.150 |
Why?
|
| Male | 17 | 2021 | 20025 | 0.150 |
Why?
|
| Amino Acid Sequence | 7 | 2012 | 1180 | 0.150 |
Why?
|
| Aging | 2 | 2002 | 664 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2018 | 325 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 59 | 0.150 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2016 | 10 | 0.140 |
Why?
|
| Microglia | 2 | 2021 | 166 | 0.140 |
Why?
|
| Drug Design | 1 | 2018 | 162 | 0.140 |
Why?
|
| Immunity, Cellular | 3 | 2015 | 70 | 0.140 |
Why?
|
| Lymphocyte Count | 4 | 2007 | 46 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 59 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2016 | 86 | 0.140 |
Why?
|
| Chromones | 1 | 2016 | 54 | 0.140 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 20 | 0.140 |
Why?
|
| Macrophages | 2 | 2011 | 439 | 0.140 |
Why?
|
| Dendritic Cells | 2 | 2013 | 113 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2016 | 80 | 0.140 |
Why?
|
| Intestines | 1 | 2016 | 64 | 0.140 |
Why?
|
| Vaccines, Attenuated | 1 | 2016 | 72 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 234 | 0.130 |
Why?
|
| Bacterial Proteins | 2 | 2010 | 540 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 33 | 0.130 |
Why?
|
| Clone Cells | 2 | 2007 | 47 | 0.130 |
Why?
|
| Phagocytosis | 1 | 2015 | 69 | 0.130 |
Why?
|
| Portraits as Topic | 1 | 2015 | 1 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 149 | 0.130 |
Why?
|
| Sepsis | 1 | 2016 | 80 | 0.130 |
Why?
|
| Anniversaries and Special Events | 1 | 2015 | 5 | 0.130 |
Why?
|
| Kinetics | 2 | 2010 | 708 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2015 | 81 | 0.120 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 15 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 49 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2013 | 16 | 0.120 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2013 | 9 | 0.120 |
Why?
|
| Receptors, HIV | 1 | 2013 | 5 | 0.110 |
Why?
|
| Aluminum Hydroxide | 2 | 2004 | 7 | 0.110 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2013 | 11 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 218 | 0.110 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 70 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 84 | 0.110 |
Why?
|
| Aquaporin 4 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2013 | 43 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 2 | 2013 | 186 | 0.110 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 1568 | 0.110 |
Why?
|
| Immunoassay | 1 | 2012 | 61 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 27 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 481 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2010 | 444 | 0.100 |
Why?
|
| Time Factors | 4 | 2017 | 1742 | 0.100 |
Why?
|
| Fallopian Tubes | 1 | 2011 | 17 | 0.100 |
Why?
|
| Receptors, IgE | 1 | 2011 | 23 | 0.100 |
Why?
|
| Brain Chemistry | 3 | 2012 | 140 | 0.100 |
Why?
|
| Antibodies, Blocking | 1 | 2011 | 11 | 0.100 |
Why?
|
| Asparaginase | 1 | 2011 | 4 | 0.100 |
Why?
|
| Lymph Nodes | 3 | 2005 | 67 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1198 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2002 | 55 | 0.100 |
Why?
|
| Axons | 1 | 2011 | 108 | 0.090 |
Why?
|
| Peptides | 1 | 2013 | 320 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 98 | 0.090 |
Why?
|
| Phagosomes | 1 | 2010 | 30 | 0.090 |
Why?
|
| Models, Animal | 1 | 2011 | 134 | 0.090 |
Why?
|
| Glycoproteins | 3 | 2005 | 106 | 0.090 |
Why?
|
| Lung | 2 | 2010 | 446 | 0.090 |
Why?
|
| Endopeptidases | 2 | 2008 | 59 | 0.090 |
Why?
|
| Butadienes | 1 | 2009 | 29 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2009 | 41 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2009 | 29 | 0.090 |
Why?
|
| Administration, Intranasal | 5 | 2009 | 79 | 0.090 |
Why?
|
| Escherichia coli Proteins | 1 | 2011 | 126 | 0.090 |
Why?
|
| Nitriles | 1 | 2009 | 69 | 0.090 |
Why?
|
| Microwaves | 3 | 2014 | 24 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 122 | 0.080 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2008 | 4 | 0.080 |
Why?
|
| Contact Inhibition | 1 | 2008 | 4 | 0.080 |
Why?
|
| Acute Disease | 3 | 2005 | 147 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 147 | 0.080 |
Why?
|
| Guinea Pigs | 2 | 2007 | 145 | 0.080 |
Why?
|
| Vaginal Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 239 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2008 | 149 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 448 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 204 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 27 | 0.080 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 12 | 0.080 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2007 | 19 | 0.070 |
Why?
|
| DNA Replication | 1 | 2008 | 152 | 0.070 |
Why?
|
| Aged | 2 | 2017 | 6741 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 29 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2006 | 30 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 2016 | 89 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 173 | 0.070 |
Why?
|
| Age Factors | 2 | 2007 | 1033 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2009 | 517 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2003 | 24 | 0.070 |
Why?
|
| Allergens | 1 | 2006 | 63 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 48 | 0.070 |
Why?
|
| Glutamate Decarboxylase | 2 | 1996 | 19 | 0.060 |
Why?
|
| Vaccines, Synthetic | 2 | 2018 | 72 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 252 | 0.060 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 2 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 1996 | 68 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2018 | 52 | 0.060 |
Why?
|
| Skin Transplantation | 1 | 2004 | 4 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 295 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2004 | 38 | 0.060 |
Why?
|
| Myocardium | 2 | 2021 | 235 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2003 | 435 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 47 | 0.060 |
Why?
|
| Interleukin-5 | 2 | 2000 | 7 | 0.060 |
Why?
|
| Immune Sera | 1 | 2003 | 59 | 0.060 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2003 | 28 | 0.050 |
Why?
|
| Magnetics | 2 | 2012 | 36 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 26 | 0.050 |
Why?
|
| Antibody Formation | 2 | 2006 | 74 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2002 | 8 | 0.050 |
Why?
|
| Wound Healing | 1 | 2003 | 70 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 81 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2001 | 31 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2001 | 111 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 628 | 0.050 |
Why?
|
| Epitopes | 3 | 2005 | 148 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 14 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 213 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2003 | 162 | 0.050 |
Why?
|
| Clonal Deletion | 1 | 2000 | 3 | 0.050 |
Why?
|
| Vaccines | 1 | 2002 | 55 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2003 | 121 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 610 | 0.050 |
Why?
|
| Glycosides | 1 | 2000 | 21 | 0.050 |
Why?
|
| Vagina | 2 | 2011 | 81 | 0.050 |
Why?
|
| Triterpenes | 1 | 2000 | 14 | 0.050 |
Why?
|
| Cell Death | 2 | 2012 | 267 | 0.050 |
Why?
|
| Protein Binding | 2 | 2018 | 972 | 0.040 |
Why?
|
| Mycobacterium Infections | 1 | 1999 | 16 | 0.040 |
Why?
|
| Arthritis, Reactive | 1 | 1998 | 1 | 0.040 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1998 | 5 | 0.040 |
Why?
|
| Lyme Disease | 1 | 1998 | 16 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2000 | 286 | 0.040 |
Why?
|
| Lipoproteins | 1 | 1998 | 64 | 0.040 |
Why?
|
| Antigens, Protozoan | 1 | 2018 | 72 | 0.040 |
Why?
|
| Computational Biology | 2 | 2011 | 293 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1998 | 42 | 0.040 |
Why?
|
| Algorithms | 2 | 2017 | 465 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2017 | 64 | 0.040 |
Why?
|
| Patient Selection | 1 | 2018 | 164 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 202 | 0.040 |
Why?
|
| Immunity | 1 | 2016 | 53 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2015 | 4 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 12 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 15 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 220 | 0.030 |
Why?
|
| Spectrin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Synapsins | 1 | 2014 | 7 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2018 | 318 | 0.030 |
Why?
|
| Alleles | 2 | 2006 | 321 | 0.030 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2013 | 3 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chimera | 1 | 2013 | 15 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 22 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 18 | 0.030 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2013 | 35 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 27 | 0.030 |
Why?
|
| Immunity, Active | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chlamydia trachomatis | 1 | 2013 | 68 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 1095 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2012 | 195 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 885 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 62 | 0.030 |
Why?
|
| Perforin | 1 | 2011 | 10 | 0.020 |
Why?
|
| Directed Molecular Evolution | 1 | 2011 | 5 | 0.020 |
Why?
|
| Genetic Drift | 1 | 2011 | 3 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 182 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 550 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 302 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 101 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 1378 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Peptide Library | 1 | 2011 | 25 | 0.020 |
Why?
|
| Mannose-Binding Lectins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Organelles | 1 | 2010 | 24 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2010 | 34 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 36 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2011 | 109 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 66 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 859 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2010 | 102 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 238 | 0.020 |
Why?
|
| Hela Cells | 1 | 2011 | 366 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 109 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 144 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 207 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 408 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 39 | 0.020 |
Why?
|
| Adult | 4 | 2015 | 11712 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2008 | 35 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 433 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 515 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1990 | 182 | 0.020 |
Why?
|
| beta-Glucans | 1 | 2007 | 10 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 1015 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 212 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 808 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1987 | 20 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1987 | 18 | 0.020 |
Why?
|
| Isoflavones | 1 | 2007 | 129 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2006 | 3 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2006 | 20 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 64 | 0.020 |
Why?
|
| Heart | 1 | 2007 | 180 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 118 | 0.020 |
Why?
|
| Plant Proteins | 1 | 2006 | 93 | 0.020 |
Why?
|
| Islets of Langerhans | 2 | 1996 | 8 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 1996 | 45 | 0.020 |
Why?
|
| Sex Factors | 1 | 2007 | 898 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2003 | 8 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 22 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 88 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 172 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 172 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2002 | 7 | 0.010 |
Why?
|
| Carcinogens | 1 | 2003 | 124 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2002 | 35 | 0.010 |
Why?
|
| Influenza A virus | 1 | 2002 | 27 | 0.010 |
Why?
|
| Benzo(a)pyrene | 1 | 2003 | 126 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 484 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2003 | 272 | 0.010 |
Why?
|
| Thymectomy | 1 | 2000 | 1 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2002 | 174 | 0.010 |
Why?
|
| DNA Damage | 1 | 2003 | 352 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2000 | 21 | 0.010 |
Why?
|
| GATA3 Transcription Factor | 1 | 2000 | 4 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 689 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2000 | 25 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2000 | 2 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 578 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2000 | 75 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 381 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 224 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 286 | 0.010 |
Why?
|
| Alum Compounds | 1 | 1999 | 1 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2000 | 174 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1999 | 71 | 0.010 |
Why?
|
| Stem Cells | 1 | 2000 | 141 | 0.010 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1998 | 1 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1998 | 4 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1998 | 43 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1998 | 83 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1998 | 52 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2000 | 539 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1996 | 16 | 0.010 |
Why?
|
| Middle Aged | 2 | 2002 | 10129 | 0.010 |
Why?
|
| Leucovorin | 1 | 1990 | 5 | 0.010 |
Why?
|
| Child | 1 | 1998 | 3131 | 0.010 |
Why?
|
| Vincristine | 1 | 1990 | 14 | 0.010 |
Why?
|
| Prednisone | 1 | 1990 | 27 | 0.010 |
Why?
|
| Methotrexate | 1 | 1990 | 23 | 0.010 |
Why?
|
| Bleomycin | 1 | 1990 | 20 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1990 | 54 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1990 | 84 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1990 | 128 | 0.010 |
Why?
|
| Adolescent | 1 | 1998 | 5363 | 0.000 |
Why?
|
| HLA-A2 Antigen | 1 | 1987 | 3 | 0.000 |
Why?
|
| HLA-B7 Antigen | 1 | 1987 | 2 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1987 | 12 | 0.000 |
Why?
|
| Transfection | 1 | 1987 | 523 | 0.000 |
Why?
|